Project Grant R01CA303071
Award Date 6/16/26
Completion Date 5/31/31
Dollars Obligated $483K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $396,377 Project Grant to the University of Texas at Austin on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The research project, with a completion date of April 30, 2028, integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Project Grant Award Summary The University of Texas Health Science Center at San Antonio received a $433,125 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2026 through January 31, 2031. This award supports fundamental research on the spatiotemporal regulation of DNA metabolism pathways, specifically investigating how homologous recombination (HR) proteins are...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. This five-year research initiative focuses on mechanistic characterization of benzothiazepinone inhibition of NVL (Norovirus-Like), an essential AAA+ adenosine triphosphatase (ATPase) enzyme involved in ribosomal large subunit (60S)...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This five-year research project investigates the molecular mechanisms by which the KEAP1-NRF2 (Kelch-like ECH-associated protein 1–Nuclear factor erythroid 2-related factor 2) redox-sensing pathway regulates CD8 T cell adaptation to...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $771,811 Project Grant effective June 1, 2026, through May 31, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports research aimed at identifying small molecule activators of Type I Interferon signaling to enhance cancer treatment efficacy. The project addresses a critical gap in immunotherapy by developing inhibitors targeting USP18, a ubiquitin protease that suppresses...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Health Science Center at San Antonio (UTHSCSA) a $609,846 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. This project, titled "Targeting Mucin-Type O-Glycosylation for EGFR Mutant Non-Small Cell Lung Cancer," seeks to identify novel therapeutic approaches for non-small cell lung cancer (NSCLC) patients with epidermal...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...